Caribou Biosciences (CRBU) Accounts Payables (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Accounts Payables data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 9.55% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 9.55% decrease from a year earlier, with the FY2025 full-year figure at $5.8 million, up 133.56% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.5 million, down from $5.8 million in the prior quarter.
• Over the last five years, Accounts Payables for CRBU reached as high as $5.9 million in Q1 2024 and fell as low as $426000.0 in Q2 2022.
• Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $3.1 million in 2023.
• Across the five-year window, Accounts Payables plunged 89.43% in 2022 and jumped 940.61% in 2023, its largest moves.
• Year by year, Accounts Payables stood at $1.1 million in 2022, then jumped by 172.25% to $3.1 million in 2023, then retreated by 20.64% to $2.5 million in 2024, then soared by 133.56% to $5.8 million in 2025, then slumped by 39.43% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $3.5 million in Q1 2026, $5.8 million in Q4 2025, and $3.8 million in Q3 2025.